Browse > Article

Effects of Fractionated Stereotactic Radiotherapy for Primary Hepatocellular Carcinoma  

Choi Byeong Ock (Department of Radiation Oncology, The Catholic University of Korea College of Medicine)
Kang Ki Mun (Department of Radiation Oncology, Gyengsang National University College of Medicine)
Jang Hong Seok (Department of Radiation Oncology, The Catholic University of Korea College of Medicine)
Lee Snag-wook (Department of Radiation Oncology, University of Ulsan)
Kang Young Nam (Department of Radiation Oncology, The Catholic University of Korea College of Medicine)
Chai Gyu Young (Gyeongsang Institute of Health Sciences)
Choi Ihl Bhong (Department of Radiation Oncology, The Catholic University of Korea College of Medicine)
Publication Information
Radiation Oncology Journal / v.23, no.2, 2005 , pp. 92-97 More about this Journal
Abstract
Purpose : Reports on the outcome of curative radiotherapy for the primary hepatocellular carcinoma (HCC) are rarely encountered in the literature. in this study, we report our experience of a clinical trial where fractionated stereotactic radiotherapy (SRT) was used in treating a primary HCC. Materials and Methods : A retrospective analysis was peformed on 20 patients who had been histologically diagnosed as HCC and treated by fractionated SRT. The long diameter of tumor measured by CT was $2\~6.5$ cm (average: 3.8 cm). A single dose of radiation used in fractionated SRT was S or 10 Gy: each dose was prescribed based on the planning target volume and normalized to $85\~99\%$ isocenter dose. Patients were treated $3\~5$ times per week for 2 weeks, with each receiving a total dose of 50 Gy (the median dose: 50 Gy). The follow up period was $\~55$ months (the median follow up period: 23 months). Results : The response rate was $50\%$ (12 patients), with 4 patients showing complete response ($20%$), 8 patients showing partial response ($40\%$), and 8 patients showing stable disease ($40\%$). The 1-year and 2-year survival rates were $70.0\%$ and $43.1\%$, respectively, and the median survival time was 20 months. The 1-year and 2-year disease free survival rates were $65\%$ and $32.5\%$, respectively, and the median disease-free survival rate was 19 months. Some acute complications of the treatment were noted as follows: dyspepsia in 12 patients ($60\%$), nausea/emesis in 8 patients ($40\%$), and transient liver function impairment in 6 patients ($30\%$). However, there was no treatment related death. Conclusion : The study indicates that fractionated SRT is a relatively safe and effective method for treating primary HCC. Thus, fractionated SRT may be suggested as a local treatment for HCC of small lesion and containing a single lesion, when the patients are inoperable or operation is refused by the patients. We thought that fractionated SRT is a challenging treatment modality for the HCC.
Keywords
Hepatocellular carninoma; Fractionated stereotactic radiotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Okuda K, Ohtsuki T, Obata H, et al. Natural histology of hepatocellular carcinoma and prognosis in relation to treatment. study of 850 patients. Cancer 1985;56:918-928   DOI   PUBMED   ScienceOn
2 Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990;65:1104-1110   DOI   PUBMED   ScienceOn
3 Seong J, Park HC, Han KH, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003;27:30-35   DOI   ScienceOn
4 Sato M, Uematsu M, Yamamoto F, et al. Feasibility of frameless stereotactic high dose radiation therapy for primary or metastatic liver cancer. J Radiosurg 1998;1:233-238   DOI   ScienceOn
5 Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994;33:677-683   DOI   ScienceOn
6 Lax I, Blomgren H, Larson D, Naslund I. Extracranial stereotactic radiosurgery of licalized targets. J Radiosurg 1998;66:1142-1150
7 Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000;47:435-442   DOI   ScienceOn
8 Kang KM, Choi IB, Kim IA, et al. Preliminary result in patients with primary hepatoma treated with stereotactic radiotherapy. J Korean Soc Ther Radiol Oncol 2001;19:34-39
9 Jones D, Christopherson DA, Washington JT, et al. A frameless method for stereotactic radiotherapy. Br J Radiol 1993;66:1142-1150   DOI   ScienceOn
10 Wada H, Takai Y, Nemoto K, Yamada S. Univariated analysis of factors correlated with tumor control probability of three dimensional conformal hypofractionated high dose radiotherapy for small pulmonary or hepatic tumors. Int J Radiat Oncol Biol Phys 2004;58:1114-1120   DOI   ScienceOn
11 Sims E, Doughty D, Macaulay E, et al. Stereotactically delivered cranial radiation therapy: a ten-year experience of linacbased radiosurgery in the UK. Clin Oncol 1999;11:303-320   DOI   ScienceOn
12 Ulm AJ, Friedman WA, Bova FJ, Bradshaw P, Amdur RJ, Mendenhall WM. Linear accelerator radiosurgery in the treatment of brain metastases. Neurosurgery 2004;55:1076-1085   DOI   ScienceOn
13 Koong AC, Le QT, Ho A, et al. Phase I study stereotactic radiosurgery in a patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:1017-1021   DOI   ScienceOn
14 Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997;25:259-262   DOI   PUBMED   ScienceOn
15 Lee SW, Choi EK, Park HJ, et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003;40:309-315   DOI   ScienceOn
16 Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol 1995;34:861-870   DOI   ScienceOn
17 Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83   DOI
18 Horigome H, Nomura T, Nakao H, et al. Percutaneous radiofreqeuncy ablation therapy using a clustered electrode for malignant liver tumors. J Clin Gastroenterol 2001;32:418-422   DOI   ScienceOn
19 Nagata Y, Negoro Y, Aoli Y, et al. Clinical outcomes of 3D conformal hypofractionated single high dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002;52:1041-1046   DOI   ScienceOn
20 Orlando A, Cottone M, Virdone R, et al. Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection: a trial with a comparison group. Scan J Gastroenterol 1997;32:595-603   DOI
21 Murphy MJ, Marthin D, Whyte R, Hai J, Ozhasoglu C, Le QT. The effectiveness of breath holding to stabilize lung and pancreas tumors during radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:475-482   DOI   ScienceOn
22 The liver cancer study group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. An Surg 1990;211:277-287   PUBMED
23 Herfarth KK, Debus J, Lohr F, et al. Stereotactic single dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001;19:164-170   DOI
24 Bush DA, Hillebrand DJ, Slater JM, Slater JD. High dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterol 2004;127:S189-S193   DOI   ScienceOn
25 Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951;102:316-319   PUBMED
26 Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151   DOI
27 Keum KC, Park HC, Seong JS, et al. Preliminary results of 3 dimensional conformal radiotherapy for primary unresectable hepatocellular carcinoma. J Korean Soc Ther Radiol Oncol 2002;20:123-129
28 Umatsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients. Cancer 1998;82:1062-1070   DOI   PUBMED   ScienceOn